Our proprietary TCR–pMHC AI engine is an advanced artificial intelligence platform that predicts neoantigen presentation and T-cell receptor (TCR) interactions for personalized cancer vaccines and CAR-based cell therapies. By integrating structural bioinformatics with deep learning, this platform accelerates the identification of highly immunogenic epitopes, enabling the development of precisely targeted immunotherapies.